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Use of urine specific gravity to improve screening for
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Use of urine specific gravity to improve screening for albuminuria. The
albumin to creatinine ratio (ACR) can be used to measure urine albumin
excretion rates, but is inconvenient and expensive. More rapid and less
expensive screening methods estimate only albumin concentration and are
subject to errors caused by variation in urine volume. We examined
whether urine specific gravity could be used in place of urine creatinine to
correct albumin concentration for differences in urine volume in 50
patients. Urine specific gravity accurately estimated urine creatinine
concentration (r = 0.79, P < 0.001). The albumin estimated-creatinine
ratio (ACestR) in a random spot urine sample correlated with urine
albumin excretion measured in a 24-hour urine collection (r = 0.98, P <
0.001), as did the ACR (r = 0.95, P < 0.001). For determining microalbu-
minuria, the sensitivity (0.88) and specificity (0.93) of the ACestR were
similar to those of ACR (0.89 and 0.93, respectively). Unfortunately, the
sensitivity (0.63) of the Micral-Test was relatively poor, and was only
slightly improved by correcting for urine specific gravity (0.69) in this small
sample of patients. Nevertheless, these results suggest that as rapid
methods for measuring urine albumin concentration improve, combining
them with urine specific gravity might produce a less expensive and more
convenient alternative to the ACR.
The measurement of urine albumin excretion is becoming an
increasingly important tool for clinicians. The detection of mi-
croalbuminuria, for example, is a useful predictor of subsequent
nephropathy in patients with diabetes [1, 21. Microalbuminuria
and albuminuria have also been shown to be associated with
increased cardiovascular disease risk in patients with and without
diabetes [3—7]. The gold standard for measuring urine albumin
excretion is a timed urine collection, but inconvenience, cost, and
problems with incomplete collection make timed urine collections
difficult to use in an outpatient clinic setting. The ratio of urine
albumin concentration to urine crcatinine concentration (ACR)
has been widely adopted as a practical alternative for timed urine
collections, since it correlates closely with urine albumin excretion
rate. However, the ACR must be measured in a laboratory, and
the resulting delay diminishes the value of the ACR as a practical,
office screening test.
Recently, more rapid screening methods have been developed
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for estimating urine albumin concentration. However, variation in
the rate of diuresis may substantially alter the concentration of
albumin in the urine without changing the rate of albumin
excretion, making a simple measurement of albumin concentra-
tion less predictive [8]. We hypothesized that urine specific gravity
or relative density, which can be readily measured in the clinic,
might be used in place of urine creatinine concentration to
enhance the sensitivity and specificity of rapid screening tests for
albuminuria. We tested this hypothesis by comparing urine creat-
mine concentration with urine creatinine concentration estimated
by urine specific gravity (Cest), as well as comparing ACR with
albumin to estimated-creatinine ratio (ACestR) in 50 patients
attending renal and hypertension clinics. We also examined
whether Cest could be used to enhance the sensitivity and
specificity of a rapid screening test for albuminuria (Micral-Test®;
Boehringer-Mannheim, Gmbh, Mannheim, Germany).
METHODS
The research protocol was approved by the Hennepin County
Medical Center (HCMC) Institutional Review Board. Patients
were randomly recruited from HCMC nephrology and hyperten-
sion clinics. Each patient was carefully instructed on how to
collect a 24-hour urine sample. Upon returning to clinic, a
random, spot urine sample was also obtained.
Specific gravity, or relative density, was measured in the spot
urine samples with both a dipstick (Multistix®; Ames Division,
Miles Laboratories, Elkhart, IN, USA) and a refractometer.
There was little difference between urine specific gravity deter-
mined using the dipstick versus a refractometer [r 0.81, 95% CI
(0.75 to 0.86), P < 0.0011, therefore, only the results for the
specific gravity measured on the spot urine samples with refrac-
tometry are presented. Urine albumin concentrations were mea-
sured in the 24-hour and spot urine samples using nephelometry
with a monoclonal antibody (Behring Diagnostics, Westwood,
MA, USA). Creatinine was measured in both the 24-hour and
spot urine samples using the Jaffe method with an autoanalyzer.
Urine albumin concentration was also estimated in the spot urine
collection using the Micral-Test. The Micral-Test results were
interpreted using standard, clinical laboratory personnel. Al-
though these personnel were versed in using the test, no special
coaching or instruction was provided as part of the study. Urine
creatinine was estimated from the specific gravity by first exam-
ining the linear relationship between the two variables using the
method of least squares. The resulting regression relationship was
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Age years
Body weight kg
Height cm
Urine albumin excretion
mg/24 hr
Serum creatinine mg/dl
Creatinine clearance
mi/mini]. 73 m2
Urine creatinine excretion
mg/kg/l.73 m2/day
24-hr urine volume ml
24-hr urine specific gravity
(refractometer)
Spot urine specific gravity
(refractometer)
Renal transplant recipient
Diabetic
Hypertensive
Other nephropathy
Men
(N = 31)
48 12
(28—74)
82.1 15.2
(47.7—115.5)174 9
(152—188)
1406 4553
(3—25432)
2.2 1.6
(0.8—7.4)68.8 46.2
(5.0—207.1)
18.0 6.4
(5.0—33.0)
2560 1022
(475—5100)
1.011 0.005
(1.005—1.026)
1.013 0.006
(1.004—1.026)
18/3 1
4/31
8/31
4/31
________
350
Women
(N=19)
ci)
45±13
(24-67)
80.1 29.9
(50.0—183.2)162±7
(152—178)685 1310
-o
(3—4019)
1.6 1.2
(0.8—5.6)67.2 24.6
(12.6 —1 02.5)
16.4 6.8
(7.4—33.4)
2610 753
(1360—4100)
1.010 0.004
(1.003—1.018)
1.012 0.005
(1.005—1.022)
13/19
1/19
3/19
2/19
DISCUSSION
used to calculate urine creatinine concentration based on specific
gravity.
Correlations were examined with Pearson r-values (method of
least squares). Statistical significance was tested at an alpha of
0.05. Results are presented as means SDs. Data were analyzed
using the Statistical Package for the Social Sciences.
RESULTS
In general, the study patients appeared to be representative of
a nephrology and hypertension clinic population (Table 1). Based
on the 24-hour urine collections, 15 of 50 (30%) had normal urine
albumin excretion (< 30 mg/24 hr), 17 (34%) had microalbumin-
uria (30 to 300 mg/24 hr), and 18 (36%) had clinical albuminuria
(> 300 mg124 hr). There was a strong correlation between spot
urine creatinine concentration and spot urine specific gravity [r =
0.79, 95% CI (0.73 to 0.84), P < 0.001]; urine creatinine (mg/dl)
= 9105 specific gravity — 9121. In fact, 63% of the variability in
measured urine crcatinine concentration could he explained by
variability in urine specific gravity. Therefore, when the above
linear relationship was used to calculate urine creatinine from the
specific gravity, the calculated, or estimated value was very similar
to the measured value (Fig. 1).
The ACR determined on a random, spot urine sample corre-
lated well with the albumin excretion rate from the 24-hour urine
collection [r = 0.95, 95% Cl (0.92 to 0.97), P < 0.001; Fig. 2].
However, the correlation between albumin excretion rate and
ACcstR was equally strong [r = 0.98, 95% CI (0.96 to 0.99), P <
0.001; Fig. 3]. The sensitivity and specificity of the ACestR for
detecting microalbuminuria or greater albuminuria was similar to
that of the ACR (Table 2). Thus, these data indicated that urine
specific gravity could potentially be used in place of urine creat-
mine concentration in the determination of the ACR. The
The ideal screening test is sensitive, specific, inexpensive and
convenient. The gold standard timed urine collection is impracti-
cal for routine screening in most busy ambulatory care clinics.
Timed collections are inconvenient for patients and staff, and are
subject to collection errors that often require patients to repeat
the procedure. Timed urine collections must be sent to profes-
sional laboratories for precise determination of albumin, and
creatinine is often measured to assess the completeness of collec-
tion. Therefore, the results are not immediately available, and
screening is relatively expensive.
The ACR is easy to use in clinical practice, because it requires
only a random, spot urine sample, and minimal patient instruc-
tion. The ACR correlates well with albumin excretion from a
timed urine collection, as confirmed in the present study. How-
ever, ACR results are not immediately available for physicians to
discuss with their patients. In addition, the ACR is expensive
($53.30 in our laboratory) and requires a laboratory equipped to
perform sensitive albumin concentration assays. In many hospitals
and clinics, the ACR is a "send-out" test performed at a reference
laboratory, and results are not available for several days.
Semiquantitative, office-based tests for urinary albumin concen-
tration are available, such as the Micral-Test and the Micro-
Bumintest (Miles Laboratories) [9]. However, a major short-
coming of these tests is their susceptibility to differences in urine
albumin concentration due to differences in urine volume [8]. In
fact, any determination of urine albumin concentration, no matter
how precise, must deal with the fact that differences in urine
volume will cause substantial variability in urine albumin concen-
tration [8]. This is compensated for with the creatinine concen-
tration in the ACR. To address this problem, we tested the
hypothesis that urine specific gravity could replace urine creati-
nine in correcting urine albumin concentration for differences in
Table 1. Patient characteristics
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Fig. 1. Relationship between measured urinary creatinine concentration
and urinary creatinine concentration estimated using urine specific
gravity. P < 0.001; r = 0.79.
sensitivity and specificity of the Micral-Test were less than those
of the ACR in the small sample of patients studied (Table 2).
Perhaps because of this, the sensitivity and specificity of the
Micral-Test were not improved by correcting for differences in
urine flow using a specific gravity-estimated urine creatinine.
Data are reported as means standard deviations (ranges) or propor-
tions.
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Table 2. Comparison of different methods for screening for albuminuria
Test Cut-points (>) Sensitivity Specificity
False
positive
rate
False
negative
rate
Positive
predictive
value
Negative
predictive
value
ACR 30 mg/g 0.886 0.933 0.067 0.114 0.969 0.778
ACestR 30 mg/g 0.857 0.933 0.067 0.143 0.968 0.737
Micral-Test 10 mg/liter 0.714 0.867 0.133 0.288 0.926 0.565
Micral-Test 20 mg/liter 0.629 1.000 0.000 0.371 1.000 0.536
Micral/Cest 20 mg/g 0.686 0.800 0.200 0.314 0.889 0.522
Micral/Cest 30 mg/g 0.629 0.800 0.200 0.371 0.880 0.480
Abbreviations are: ACR, albumin to creatinine ratio; ACestR, albumin to estimated creatinine ratio; Cest, creatinine estimated by urine specific
gravity.
urine volume. Compared to urine creatinine, specific gravity can
be determined quickly and inexpensively in almost any outpatient
clinic setting. Indeed, we found that specific gravity performed as
well as urine creatinine concentration, and that the ACestR
appeared to be virtually identical to the ACR.
While the dipstick method of determining specific gravity may
be simpler, refractometry methods are more accurate. The dip-
stick specific gravity is based on measuring the ionic strength of
the urine, and is dependent on a linear relationship between ionic
strength and osmolality [9, 10]. The dipstick specific gravity
measurement is pH-dependent; results may be falsely high in
strongly acidic urine and falsely low in alkaline urine. Other
possible sources of error in the measurement of specific gravity by
dipstick are its insensitivity to heavy molecules, such as glucose,
mannitol, or very high protein concentrations. Unlike refractom-
cter methods, dipstick is unaffected by radiocontrast media.
Our results with the Micral-Test were disappointing (Table 2).
While several studies have documented excellent sensitivities with
the Micral-Test [11—14], others have reported results similar to
ours [15, 16]. A recent meta-analysis of data from urine samples of
diabetic patients reported that an important factor in determining
the utility of the Micral-Test is the prevalence of microalbumin-
uria in the population studied [17]. As the prevalence increases,
the positive predictive value increases (lower false-positive rate)
and negative predictive value decreases (higher false-negative
rate). Indeed, at a prevalence rate of 31.9% for the pooled data,
the sensitivity was higher (0.832), but the specificity was lower
(0.923) than reported in our study, in which the prevalence of
microalbuminuria and overt albuminuria was 70%.
The level of experience and training of the individual interpret-
ing the Micral-Test has been shown to be important [16]. In the
present study we provided no special training to the laboratory
personnel interpreting the test, because we wanted to closely
approximate how the test would likely be used in routine clinical
practice. The technologists who participated uniformly reported
that they had difficulty discriminating between the different shades
of red on the Micral-Test strip.
An area of clinical usefulness of a rapid test for microalbumin-
uria is in the diabetic population. One limitation of the study is
that only 5 diabetic patients were enrolled. We previously evalu-
ated 22 patients with noninsulin-dependent diabetes mellitus to
assess the feasibility of using urine specific gravity to correct for
urine volume. Using multiple linear regression analysis, with ACR
as the dependent variable, and gender, weight, body mass index
(kg/rn2), body surface area (m2), Cr * Scr (creatinine clearance
estimated by the Cockcroft and Gault equation [181 multiplied by
serum creatinine) and ACestR as independent variables, we
found a high correlation between ACR and ACestR with specific
gravity measured by dipstick and refractometer methods (r2 =
0.91 for both methods). Using an ACR of 30 mglg to define
microalbuminuria, all 22 patients were correctly classified with
ACestR.
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Fig. 3. Relationship between urinary albumin excretion rate and the
albumin to estimated-creatinine ratio measured on a separate, spot urine
sample. Urinary creatinine was estimated using urine specific gravity. P <
0.001; r 0.98.
10000
Fig. 2. Relationship between urinary albumin excretion rate and albu-
min to creatinine ratio measured on a separate, spot urine sample. P <
0.001; r = 0.95.
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Perhaps it should not be surprising that the urine specific
gravity did not improve the sensitivity or specificity of the Micral-
Test. In addition to the shortcomings of the Micral-Test itself, the
relatively small sample size in this study may have made it
impossible to see any improvement in the test results with a
specific gravity correction. The results with ACestR suggest that a
more precise, but rapid method for measuring urine albumin
concentration could be advantageously combined with urine
specific gravity in designing a more cost-effective and convenient
screening test for albuminuria and microalbuminuria.
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